Literature DB >> 15004331

Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease.

Joseph F Quinn1, Kathleen S Montine, Milar Moore, Jason D Morrow, Jeffrey A Kaye, Thomas J Montine.   

Abstract

We report the first longitudinal analysis of cerebrospinal fluid (CSF) F2-isoprostanes (IsoPs), quantitative in vivo biomarkers of lipid peroxidation, in patients with mild Alzheimer's disease (AD). CSF F2-IsoPs (i) were significantly increased in patients followed over one year, (ii) correlated with some clinical indices of dementia following correction for variation in ventricular enlargement, and (iii) were significantly lower in patients who used both alpha-tocopherol and vitamin C.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15004331     DOI： 10.3233/jad-2004-6110

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN： 1387-2877            Impact factor:   4.472


  23 in total

Review 1.  Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.

Authors:  D Allan Butterfield; Miranda L Bader Lange; Rukhsana Sultana
Journal:  Biochim Biophys Acta       Date:  2010-02-20

2.  Comparative proteomic profiling of cerebrospinal fluid between living and post mortem ALS and control subjects.

Authors:  Srikanth Ranganathan; Georgina C B Nicholl; Sarah Henry; Fran Lutka; Ramasri Sathanoori; David Lacomis; Robert Bowser
Journal:  Amyotroph Lateral Scler       Date:  2007-08-03

Review 3.  Cognitive impairment and dementia in patients with Parkinson disease.

Authors:  James B Leverenz; Joseph F Quinn; Cyrus Zabetian; Jing Zhang; Kathleen S Montine; Thomas J Montine
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

Review 4.  Role of cerebrospinal fluid and plasma biomarkers in the diagnosis of neurodegenerative disorders and mild cognitive impairment.

Authors:  Luis F Gonzalez-Cuyar; Joshua A Sonnen; Kathleen S Montine; C Dirk Keene; Thomas J Montine
Journal:  Curr Neurol Neurosci Rep       Date:  2011-10       Impact factor: 5.081

Review 5.  Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.

Authors:  Kaj Blennow; Bruno Dubois; Anne M Fagan; Piotr Lewczuk; Mony J de Leon; Harald Hampel
Journal:  Alzheimers Dement       Date:  2014-05-03       Impact factor: 21.566

Review 6.  Biomarkers of oxidative damage and inflammation in Alzheimer's disease.

Authors:  Douglas Galasko; Thomas J Montine
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

7.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.

Authors:  M J de Leon; L Mosconi; J Li; S De Santi; Y Yao; W H Tsui; E Pirraglia; K Rich; E Javier; M Brys; L Glodzik; R Switalski; L A Saint Louis; D Pratico
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

Review 8.  Why pleiotropic interventions are needed for Alzheimer's disease.

Authors:  Sally A Frautschy; Greg M Cole
Journal:  Mol Neurobiol       Date:  2010-05-02       Impact factor: 5.590

Review 9.  Lipid peroxidation triggers neurodegeneration: a redox proteomics view into the Alzheimer disease brain.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2012-10-05       Impact factor: 7.376

Review 10.  Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models.

Authors:  Joshua A Sonnen; John C Breitner; Mark A Lovell; William R Markesbery; Joseph F Quinn; Thomas J Montine
Journal:  Free Radic Biol Med       Date:  2008-04-24       Impact factor: 7.376
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.